Stay updated on Pembrolizumab as AML Post-Remission Treatment Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.

Latest updates to the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedA new revision tag v3.6.3 replaced v3.6.2 on the page. This indicates a small update to the page template or content management.SummaryDifference0.1%

- Check16 days agoChange DetectedThe page revision has been updated from v3.6.0 to v3.6.2, indicating a minor backend/UI update. This change does not alter the study details or their presentation to users.SummaryDifference0.1%

- Check31 days agoChange DetectedThe page now indicates no participants are being sought and adds new help/navigation items (How to Read a Study Record, Common Questions, How to Join a Study). It also updates the Intervention/Treatment label formatting and changes the release note from Revision: v3.5.5 to Revision: v3.6.0.SummaryDifference0.5%

- Check38 days agoChange DetectedRevision updated to v3.5.5, indicating a software version update for the page. This change does not modify study details or other user-facing content.SummaryDifference0.1%

- Check59 days agoChange DetectedThe page has updated its revision number from v3.5.3 to v3.5.4, indicating a minor site update. The update does not alter the displayed study details or eligibility criteria.SummaryDifference0.1%

- Check74 days agoChange DetectedThe page shows a revision update from v3.5.2 to v3.5.3, representing a new build of the site. This update does not alter the study details or any information presented to users.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab as AML Post-Remission Treatment Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab as AML Post-Remission Treatment Clinical Trial page.